ABSTRACT
Background SARS-CoV-2 antibody tests have undergone a remarkable improvement in performance. However, due to the low seroprevalence in several areas, very high demands are made on their specificity. Furthermore, the low antibody-response in some individuals requires high test sensitivity to avoid underestimating true seroprevalence. Optimization of testing has been reported through lowering manufacturer cut-offs to improve SARS-CoV-2 assay sensitivity or by combining two tests to improve specificity at the cost of sensitivity. However, these strategies have thus far been used in isolation of each other.
Methods To increase sensitivity, cut-offs of three commercially available SARS-CoV-2 automated assays (Roche, Abbott, and DiaSorin) were reduced according to published values in a pre-pandemic specificity cohort (n=1117) and a SARS-CoV-2 positive cohort (n=64). All three testing systems were combined in an orthogonal approach with a confirmatory test, which was one of the remaining automated assays or one of two commercial ELISAs directed against the spike protein receptor binding-domain (RBD) or the nucleocapsid antigen (NP).
Results The modified orthogonal test strategy resulted in an improved specificity of at least 99.8%, often even 100%, in all 12 tested combinations with no significant decline in sensitivity. In our cohort, regardless of whether the assays were used for screening or confirmation, combining Roche and Abbott delivered the best overall performance (+∼10% sensitivity compared to the single tests and 100% specificity).
Conclusion Here we propose a novel orthogonal assay strategy that approaches 100% specificity while maintaining or even significantly improving the screening test’s sensitivity.
Competing Interest Statement
The Department of Laboratory Medicine (TP, NP, MOK, TK, PQ, RM, PM, AR, RS, OFW, CJB, HH) holds a grant for evaluating an in-vitro diagnostic device from Roche. Furthermore, the Department received financial compensations for advertising space at scientific symposia from Roche, Abbott, and DiaSorin. NP received a travel grant from DiaSorin. SH does receive unrestricted research grants (GSK, Boehringer, Menarini, Chiesi, Astra Zeneca, MSD, Novartis, Air Liquide, Vivisol, Pfizer, TEVA) for the Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, and is on advisory boards for GSK, Boehringer Ingelheim, Novartis, Menarini, Chiesi, Astra Zeneca, MSD, Roche, Abbvie, Takeda, and TEVA for respiratory oncology and COPD. OCB reports grants from GSK, grants from Menarini, grants from Boehringer Ingelheim, grants from Astra, grants from MSD, grants from Pfizer, and grants from Chiesi, outside the submitted work. PQ is advisory board member for Roche Austria, and reports personal fees from Takeda, outside the submitted work. CJB is board member of Technolcone.
Funding Statement
There was no external funding received. However, test kits for the Technoclone ELISAs were kindly provided by the manufacturer free of charge.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Medical University of Vienna (1424/2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available for interested researchers upon request from the corresponding author.
List of abbreviations
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- RT-PCR
- Reverse transcriptase-polymerase chain reaction
- ECLIA
- Electrochemiluminescence assay
- 95% CI
- 95% confidence interval
- CMIA
- Chemiluminescent microparticle immunoassay
- CLIA
- Chemiluminescence immunoassay
- PPV
- Positive predictive value
- NPV
- Negative predictive value
